Johnson & Johnson (LON:0R34)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 479.10B +39.3% |
| Revenue (ttm) | 74.10B +8.1% |
| Net Income | 15.92B -7.2% |
| EPS | 6.53 -7.6% |
| Shares Out | n/a |
| PE Ratio | 30.22 |
| Forward PE | 22.20 |
| Dividend | 4.03 (2.16%) |
| Ex-Dividend Date | Aug 25, 2026 |
| Volume | 26,612 |
| Open | 265.50 |
| Previous Close | 263.05 |
| Day's Range | 245.18 - 268.03 |
| 52-Week Range | 184.47 - 281.20 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 13, 2026 |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription... [Read more]
Financial Performance
In 2025, Johnson & Johnson's revenue was $94.19 billion, an increase of 6.05% compared to the previous year's $88.82 billion. Earnings were $26.80 billion, an increase of 90.56%.
Financial numbers in USD Financial StatementsNews
J&J raises its forecast again. CFO Joe Wolk on what's driving it
Johnson & Johnson raised its full-year forecast again on October 13, 2026, and CFO Joe Wolk tells Yahoo Finance's Julie Hyman that pharmaceuticals led the way, with oncology up 17% and immunology retu...
Johnson & Johnson shares fall following earnings
Johnson & Johnson stock is tumbling despite the company raising its forecast again for full-year earnings and revenue.
Tuesday's First Moves: WFC Mixed Earnings, JNJ Beat & Raise, DPZ Slides
JPMorgan Chase (JPM) earnings showed a double miss and gained after the opening bell while Wells Fargo (WFC) showed mixed results and traded lower. Diane King Hall offers a closer look into the latter...
J&J Medtech Sales Disappoint, Considers Orthopedic Spinoff
Johnson & Johnson reported a 2.5% rise in medical technology sales, missing estimates, and is leaning toward a spinoff of its orthopedics business. Madison Muller has more on "Bloomberg Open Interest.
Johnson & Johnson says focusing on improving performance of MedTech business
Expects stronger Q4 “and beyond” for MedTech.
Johnson & Johnson says continues to ‘invest strategically’ in R&D
Says Q3 results driven by innovative medicines business. Says drivers underpinning guidance “remain firmly in place.” “Remains confident” in FY26 guidance for $21B in free cash flow. Published first o...
Johnson & Johnson: Internal investments will propel double-digit growth by 2030
Says double-digit growth by the end of the decade guidance does not assume any inorganic additions.
Johnson & Johnson says product launches ‘gaining significant traction’
Says goal is to become number one oncology company by 2030. Expects Tremfya to become $10B franchise over time. Says company is “built for durable growth.” Expects to finish 2026…
Johnson & Johnson Earnings Call Transcript: Q3 2026
Q3 operational sales rose 6% to $25.4B, led by Innovative Medicine, while MedTech growth lagged expectations. FY 2026 sales guidance was raised, with adjusted EPS guidance of $10.95–$11.05 operationally and a continued path to double-digit growth by decade-end.
Johnson & Johnson Earnings release: Q3 2026
Johnson & Johnson released its Q3 2026 earnings on October 13, 2026, summarizing the period's financial results.
Johnson & Johnson Slides: Q3 2026
Johnson & Johnson has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 13, 2026.
Johnson & Johnson Stock Falls Despite Beating Q3 Expectations – Here’s Why
Johnson & Johnson ($JNJ) reported better-than-expected third-quarter 2026 results on Tuesday, driven by strong pharmaceutical sales. However, JNJ stock fell in premarket trading as slower growth in it...
J&J beats earnings estimates; Middle East conflict weighs on medical device sales
Johnson & Johnson reported a slightly higher-than-expected profit on Tuesday, driven by strong sales of immune disease treatment Tremfya, but geopolitical issues, including the Middle East conflict, ...
Johnson & Johnson Hikes Earnings Guidance but Pharma Growth Masks a MedTech Stumble
Johnson & Johnson says it is working to improve results in its medical-device business, where surgery revenue fell for the latest quarter.
J&J Is Leaning Toward Spinning Out Its Hips-And-Knees Business
Johnson & Johnson is “leaning” toward spinning out the hips-and-knees business that the company has been looking to hive off, Chief Financial Officer Joseph Wolk said.
Johnson & Johnson reports Q3 adjusted EPS $2.59, consensus $2.53
Reports Q3 revenue $25.4B, consensus $25.38B. “Johnson & Johnson’s strong third-quarter performance and increased sequential growth reflect the accelerating momentum of our focused portfolio,” said Jo...
Johnson & Johnson raises FY26 adjusted EPS view to $11.05-$11.15
Prior view was $10.96-$11.11, consensus $11.08. Raises FY26 estimated reported sales view to $101B-$101.4B from $100.8B-$101.4B, consensus $101.38B.
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2026 of $1.34 per share on the co...
Johnson & Johnson reports Q3 2026 results, raises 2026 guidance
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2026. “Johnson & Johnson's strong third-quarter performance and increased sequential growt...
Johnson & Johnson reports three-year data from Phase 3 GALAXI 2 and 3 studies
Johnson & Johnson announced new three-year data from the Phase 3 GALAXI 2 and 3 studies showing durable efficacy and a consistent safety profile for TREMFYA in adults with moderately…
Johnson & Johnson: Tremfaya study shows consistent perianal fistula remission
Johnson & Johnson announced new Phase 3 data showing consistent combined fistula remission outcomes with TREMFYA across clinically important subgroups of adults with Crohn’s disease with perianal fist...
TREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease
New long-term data showed clinical remission rates of up to 94% and endoscopic remission rates of up to 61% in adults with moderately to severely active Crohn's disease 88% of patients achieved 90-day...
New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups
New prespecified analyses showed consistent findings across clinically important and difficult to treat subgroups, including patients with prior biologic exposure Findings build on first positive resu...
Will Johnson & Johnson Stock (JNJ) Rise or Fall After Q3 Earnings?
Johnson & Johnson stock was up slightly on Monday ahead of the company’s earnings report, which could be a strong catalyst for JNJ shares.
Johnson & Johnson Q3 Earnings on October 13: Analysts See 10% Upside in JNJ Stock
Medical group Johnson & Johnson ($JNJ) reports its Q3 earnings tomorrow – October 13. Wall Street expects the company to report earnings per share of $2.52, down from $2.80 in…